Dimensional Fund Advisors LP Sells 50,011 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK)

Dimensional Fund Advisors LP trimmed its position in Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report) by 7.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 657,355 shares of the biotechnology company's stock after selling 50,011 shares during the quarter. Dimensional Fund Advisors LP owned about 4.49% of Anika Therapeutics worth $10,820,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Barclays PLC increased its position in Anika Therapeutics by 66.6% in the third quarter. Barclays PLC now owns 32,664 shares of the biotechnology company's stock worth $806,000 after purchasing an additional 13,054 shares during the last quarter. R Squared Ltd purchased a new position in shares of Anika Therapeutics in the 4th quarter worth $27,000. Bank of New York Mellon Corp increased its holdings in shares of Anika Therapeutics by 20.8% in the 4th quarter. Bank of New York Mellon Corp now owns 50,529 shares of the biotechnology company's stock worth $832,000 after buying an additional 8,711 shares during the last quarter. Los Angeles Capital Management LLC increased its holdings in shares of Anika Therapeutics by 9.1% in the 4th quarter. Los Angeles Capital Management LLC now owns 11,700 shares of the biotechnology company's stock worth $193,000 after buying an additional 980 shares during the last quarter. Finally, Capital Management Corp VA raised its position in shares of Anika Therapeutics by 12.1% during the 4th quarter. Capital Management Corp VA now owns 325,545 shares of the biotechnology company's stock valued at $5,358,000 after buying an additional 35,195 shares in the last quarter. 91.53% of the stock is currently owned by hedge funds and other institutional investors.

Anika Therapeutics Price Performance

Shares of ANIK stock opened at $11.64 on Friday. The stock has a 50 day simple moving average of $14.80 and a 200-day simple moving average of $16.54. Anika Therapeutics, Inc. has a 1-year low of $11.48 and a 1-year high of $29.12. The company has a market cap of $166.93 million, a price-to-earnings ratio of -1.75 and a beta of 0.76.

Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of $0.09 by ($0.37). Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%. Analysts anticipate that Anika Therapeutics, Inc. will post -0.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ANIK. Barrington Research dropped their target price on Anika Therapeutics from $25.00 to $20.00 and set an "outperform" rating for the company in a report on Thursday, March 13th. StockNews.com raised shares of Anika Therapeutics from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Finally, B. Riley initiated coverage on shares of Anika Therapeutics in a research note on Thursday, April 17th. They issued a "buy" rating and a $21.00 target price on the stock.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.